Cargando…
Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer
Resistance to TKI treatment is a major obstacle in effective treatment of NSCLC. Besides EGFR mutation status, the mechanisms involved are largely unknown. Some evidence supports a role for microRNA 21 in modulating drug sensitivity of chemotherapy but its role in NSCLC TKI resistance still remains...
Autores principales: | Shen, Hua, Zhu, Fang, Liu, Jinyuan, Xu, Tongpeng, Pei, Dong, Wang, Rong, Qian, Yingying, Li, Qi, Wang, Lin, Shi, Zhumei, Zheng, Jitai, Chen, Qiudan, Jiang, Binghua, Shu, Yongqian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110008/ https://www.ncbi.nlm.nih.gov/pubmed/25058005 http://dx.doi.org/10.1371/journal.pone.0103305 |
Ejemplares similares
-
Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review
por: Chen, Xiaofeng, et al.
Publicado: (2013) -
MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1
por: Jin, Shidai, et al.
Publicado: (2018) -
The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro
por: Zhuang, Hong-Qing, et al.
Publicado: (2009) -
A Genetic Polymorphism in pre-miR-27a Confers Clinical Outcome of Non-Small Cell Lung Cancer in a Chinese Population
por: Xu, Jiali, et al.
Publicado: (2013) -
MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN
por: Xue, Xinying, et al.
Publicado: (2016)